Authors: Dudkin, L Dilling, MB Cheshire, PJ Harwood, FC Hollingshead, M Arbuck, SG Travis, R Sausville, EA Houghton, PJ

Citation: L. Dudkin et al., Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, CLIN CANC R, 7(6), 2001, pp. 1758-1764

Authors: Huang, SL Liu, LN Hosoi, H Dilling, MB Shikata, T Houghton, PJ

Citation: Sl. Huang et al., p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin, CANCER RES, 61(8), 2001, pp. 3373-3381

Authors: Gidding, CEM Germain, GS Dilling, MB Meeuwsen-de Boer, TGJ Ashmun, RA de Graaf, SSN Veverka, KA Kamps, WA Houghton, PJ

Citation: Cem. Gidding et al., The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma celllines and xenograft models, CANC CHEMOT, 45(1), 2000, pp. 21-30

Authors: Hosoi, H Dilling, MB Shikata, T Liu, LN Shu, L Ashmun, RA Germain, GS Abraham, RT Houghton, PJ

Citation: H. Hosoi et al., Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells, CANCER RES, 59(4), 1999, pp. 886-894